Literature DB >> 20466373

Insulin resistance and acute coronary syndrome.

G Caccamo1, F Bonura, F Bonura, G Vitale, G Novo, S Evola, G Evola, M R Grisanti, S Novo.   

Abstract

BACKGROUND: Insulin resistance (IR), which can be quantified by HOMA index (fasting glucose X fasting insulin/22.5), is considered the "primum movens" for the development of Metabolic Syndrome. Many authors have suggested that insulin resistance could raise both incidence and mortality of coronary heart disease (CHD). IR is also associated with important predictors of cardiovascular disease, as increased concentration of LDL or triglyceride, decreased concentration of HDL, high systolic blood pressure, visceral obesity. There is accumulating evidence that chronic sub-clinical inflammation, as measured by inflammatory markers as C-reactive protein (CRP) and fibrinogen, is related with insulin resistance. AIM OF THE STUDY: To clarify if insulin resistance would predict cardiovascular disease independently of the other risk factors, such as hypertension, visceral obesity or dyslipidemia, by focusing our attention on the relation between Acute Coronary Syndrome (ACS) and high HOMA index.
METHODS: We evaluated glucose and insulin levels at baseline and post-prandial phase, in order to estimate HOMA index in both the conditions; we related the data obtained with the incidence of cardiovascular events, also investigating traditional cardiovascular risk factors. The cohort included 118 patients with a clinical diagnosis of ACS and excluded those with type 1 diabetes, acute inflammatory diseases, hepatic or renal failure, disreactive disorders, autoimmunity and cancer.
SUBJECTS: Subjects were followed-up for a period of 1 year, being subdivided in three groups: (1) subjects at elevated HOMA (HOMA > or = 6); (2) subjects at intermediate HOMA (HOMA <6 and > or = 2); (3) subjects at low HOMA (HOMA < or = 2). We considered as end points new cardiovascular events, cerebrovascular events (both TIA and stroke), procedures of revascularization with angioplasty or surgery, cardiovascular death, sudden death.
RESULTS: Patients with elevated HOMA have a higher incidence of previous cardio- and cerebrovascular events (p=0.03), myocardial infarction without ST elevation (p=0.005), unstable angina (p=0.01), asymptomatic carotid plaques (p=0.05), depressed systolic function (p=0.05); we found, also, a significant statistic correlation between HOMA index and high levels of CRP, fibrinogen, serum creatinine and TnI. Cardiovascular and cerebrovascular events were registered in 61% of patients with elevated HOMA during the follow up, despite of 25% registered in the control group: so we could consider HOMA index as a negative prognostic variable, also in virtue by the statistic correlation with the inflammatory markers, whose power of prediction is already known.
CONCLUSIONS: Beyond traditional cardiovascular risk factors, insulin resistance quantified by HOMA index seems to significantly have an important prognostic role, both in primary and secondary prevention in patients with Acute Coronary Syndrome. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466373     DOI: 10.1016/j.atherosclerosis.2010.03.033

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  19 in total

1.  The Effect of Admission Renal Function on the Treatment and Outcome of Patients with Acute Coronary Syndrome.

Authors:  Zach Rozenbaum; Sydney Benchetrit; Saar Minha; Yoram Neuman; Meital Shlezinger; Ilan Goldenberg; Morris Mosseri; David Pereg
Journal:  Cardiorenal Med       Date:  2017-02-17       Impact factor: 2.041

Review 2.  PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.

Authors:  Janice V Huang; Clifford R Greyson; Gregory G Schwartz
Journal:  J Lipid Res       Date:  2012-06-08       Impact factor: 5.922

3.  Usefulness of insulin resistance estimation and the metabolic syndrome in predicting coronary atherosclerosis in type 2 diabetes mellitus.

Authors:  Nehal N Mehta; Parasuram Krishnamoorthy; Seth S Martin; Caitlin St Clair; Stanley Schwartz; Nayyar Iqbal; Seth Braunstein; Mark Schutta; Daniel J Rader; Muredach P Reilly
Journal:  Am J Cardiol       Date:  2011-02-01       Impact factor: 2.778

4.  Acute hyperglycemia and insulin resistance in acute heart failure syndromes without previously known diabetes.

Authors:  Chiara Lazzeri; Serafina Valente; Paola Attanà; Marco Chiostri; Claudio Picariello; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2011-05-05       Impact factor: 3.397

5.  Targeting energy expenditure via fuel switching and beyond.

Authors:  J G Geisler
Journal:  Diabetologia       Date:  2010-10-17       Impact factor: 10.122

6.  Insulin Resistance as a Novel Risk Factor for Post-ERCP Pancreatitis: A Pilot Study.

Authors:  Ali Riza Koksal; Salih Boga; Huseyin Alkim; Mehmet Bayram; Meltem Ergun; Canan Alkim
Journal:  Dig Dis Sci       Date:  2016-03-19       Impact factor: 3.199

Review 7.  Hyperglycemia in acute heart failure: an opportunity to intervene?

Authors:  Chiara Lazzeri; Serafina Valente; Gian Franco Gensini
Journal:  Curr Heart Fail Rep       Date:  2014-09

8.  Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART study.

Authors:  Sandra N Verhagen; Annemarie M J Wassink; Yolanda van der Graaf; Petra M Gorter; Frank L J Visseren
Journal:  Cardiovasc Diabetol       Date:  2011-11-21       Impact factor: 9.951

Review 9.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

Authors:  Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel
Journal:  Diabetes Care       Date:  2014-08-11       Impact factor: 19.112

10.  Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents.

Authors:  Yong Zhu; Kesen Liu; Maolin Chen; Yan Liu; Ang Gao; Chengping Hu; Hong Li; Huagang Zhu; Hongya Han; Jianwei Zhang; Yingxin Zhao
Journal:  Cardiovasc Diabetol       Date:  2021-07-08       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.